Atropos Health, a leader in translating real-world clinical data (RWD) into real-world evidence (RWE), has announced a strategic partnership with Ontada, a McKesson business specializing in community oncology. The collaboration aims to strengthen use cases for clinicians, researchers, and healthcare leaders to design care protocols, promote precision medicine, and create new treatments in oncology.

Ontada's connection to The US Oncology Network, a wholly owned subsidiary of McKesson, provides access to real-time data, insights, and research on how cancer is treated in community settings. This partnership will significantly enhance the Atropos Evidence Network by incorporating Ontada's specialized oncology data.

Atropos Health's automation tools produce evidence from customer data by installing GENEVA OS, its operating system for rapid healthcare evidence, into customers' internal cloud data environments and the Atropos Evidence Network. Members of the Evidence Network can leverage longitudinal patient data from participating sources, gaining access to deidentified patient records while preserving data possession and security.

"The demand for high-quality data in oncology is ever present," Brigham Hyde, CEO and cofounder of Atropos Health, said in a statement. "The Atropos Evidence Network, which will now include Ontada's RWD, includes benefits across the entire healthcare ecosystem. For health systems, the oncology multi-modal network contains the high-quality RWD necessary to generate the RWE needed for high-stakes clinical decisions."

The collaboration follows Atropos Health's March announcement of Federated Nodal Deidentification Technology, which will be added to the GENEVA OS platform and made accessible to Atropos Evidence Network members. This technology allows users to fill data gaps in patients' longitudinal records from participating network sources.

This partnership adds to Atropos Health's growing momentum in the healthcare data space. Earlier this year, the company partnered with Emory Healthcare to advance medication formulary decisions and protocols, allowing clinical questions to be answered in real-time using Atropos' platform. In January, Atropos also partnered with xCures, an AI-powered healthcare data retrieval company, to harness RWE-based insights to support patient care.

That same month, Atropos formed a partnership with Merck to generate RWE, replicate studies, and produce rapid insights and analytics on real-world data. Merck's data science teams now employ several Atropos Health services, including GENEVA OS Green Button, Atropos Evidence Network, and tools like Alexandria, Forge, and ChatRWD.

In 2024, Atropos secured $33 million in Series B funding led by Valtruis, with participation from new investors including McKesson Ventures, Merck GHI Fund, and Cencora Ventures, as well as existing investors Emerson Collective, Breyer Capital, and Presidio Ventures.